Checking out the Potential of Guselkumab in Psoriatic Arthritis

MedPage Today)– At the American College of Rheumatology (ACR) virtual conference, favorable outcomes were revealed from a stage III research study assessing the long-lasting effectiveness and security of guselkumab (Tremfya), a selective interleukin (IL)-23 inhibitor …